Compare NHP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHP | DRTS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2012 | 2021 |
| Metric | NHP | DRTS |
|---|---|---|
| Price | $16.64 | $14.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 654.1K | 492.6K |
| Earning Date | N/A | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,279,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.68 | $3.18 |
| 52 Week High | $17.46 | $15.02 |
| Indicator | NHP | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 63.87 |
| Support Level | $14.54 | $6.47 |
| Resistance Level | $17.22 | $14.75 |
| Average True Range (ATR) | 0.63 | 0.61 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 54.55 | 87.42 |
National Healthcare Properties Inc is a publicly registered real estate investment trust. It is focused on acquiring, owning, and managing a diversified portfolio of healthcare real estate assets focused on senior housing operating properties (SHOP) and outpatient medical facilities (OMF) in the United States. The company operates in two reportable business segments: SHOP and OMF. The SHOP segment consists of assisted living communities, memory care communities and independent living communities, which are focused on needs-based assisted living and memory care. The OMF segment consists of physicians' offices and examination rooms, hospitals, pharmacies, hospital ancillary service space and other outpatient services. The majority of revenue is derived from the SHOP segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.